ストックスクリーナーアプリを入手
0.94
0.00%
0.00
アフターアワーズ：
.91
-0.03
-3.19%
前日終値:
$0.94
開ける：
$0.94
24時間の取引高:
39,473
Relative Volume:
0.11
時価総額：
$62.59M
収益：
-
当期純損益:
$-86.08M
株価収益率:
-0.4357
EPS:
-2.1574
ネットキャッシュフロー:
$-72.06M
1週間 パフォーマンス:
+5.02%
1か月 パフォーマンス:
-0.22%
6か月 パフォーマンス:
-28.79%
1年 パフォーマンス:
-48.91%
1日の値動き範囲:
$0.91
$0.9837
1週間の範囲:
$0.8711
$1.0656
52週間の値動き範囲:
$0.66
$1.89
Io Biotech Inc Stock (IOBT) Company Profile
IOBT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.94 | 62.59M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Io Biotech Inc (IOBT) 最新ニュース
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - Morningstar
Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - Yahoo Finance
Melanoma FDA Approvals, Pipeline Insights, Clinical Trials Assessment and Companies | DelveInsight - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - MSN
Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor - Healio
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40) - Marketscreener.com
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - The Manila Times
IO Biotech Fast-Tracks Cancer Vaccine Trial, Completes Phase 2 Enrollment Early - StockTitan
5 Best Microbiome Companies (January 2025) - Securities.io
IO Biotech faces possible Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
IO Biotech faces possible Nasdaq delisting over low stock price - Investing.com India
IO Biotech Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement - Defense World
IO Biotech's chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Australia
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in December - MarketBeat
IO Biotech’s chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Nigeria
IO Biotech's chief medical officer acquires $26,553 in common stock - Investing.com
Io biotech general counsel Devin Smith acquires $9,720 in shares By Investing.com - Investing.com Nigeria
IO Biotech CEO Mai-Britt Zocca acquires $10,120 in company stock - Investing.com India
IO Biotech (NASDAQ:IOBT) Adopts Amended and Restated Bylaws - Defense World
Io biotech general counsel Devin Smith acquires $9,720 in shares - Investing.com India
IO Biotech CFO Amy Sullivan buys $8,482 in common stock By Investing.com - Investing.com Nigeria
IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock - MarketBeat
IO Biotech CFO Amy Sullivan buys $8,482 in common stock - Investing.com
IO Biotech Secures €57.5 Million Debt Financing from European Investment Bank - Defense World
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
IO Biotech amends bylaws and adjusts fiscal year-end By Investing.com - Investing.com UK
Cancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA - openPR
(PDF) 756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) - ResearchGate
Cancer Vaccines Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - Barchart
Cancer Vaccines Market Forecasted to Surge in Coming Years, - openPR
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight - Barchart
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: - openPR
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
IO Biotech stock hits 52-week low at $0.73 amid market challenges - Investing.com UK
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
Io Biotech Inc (IOBT) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):